Latest Information Update: 26 Sep 2016
At a glance
- Originator Kyoto University
- Mechanism of Action CDC48 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Retinal disorders
Most Recent Events
- 23 Sep 2016 Kyoto Drug Discovery & Development plans a phase I/II trial for Retinal vascular occlusion in Japan (UMIN000023979)